EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fires ...

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. East ...

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wedne ...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader bri ...

PresentationMatthias BodenstedtChief Financial Officer Good morning, good afternoon. Thank you so much for joining our Investor Day today, MoonLake Immunotherapeutics. My name is Matthias Bodenstedt, I'm the CFO of the company. And I'm sitting here on the right, Dr. Jorge Santos da Silva, our Chief Executive Officer; and Professor Kristian Reich, our Chief Scientific Officer. Together, we are very excited to walk you through a number of updates about the company. I will start with a very brief introduction, ...

Grail (NASDAQ: GRAL) stock came under even more pressure today, declining by more than 16% by 12:40 a.m. The move comes as the market continues to digest the unpalatable news that hit the market on Friday. The news wasn't good, but there is a pathway to recovery, however tenuous it might appear now. What happened to Grail stock recently I discussed the game-changing event on Friday. Simply put, the company's trial of its Galleri multi-cancer early detection (MCED) with England's National Health Service (N ...

Core Insights - Arcellx shares surged approximately 80% following the announcement of its acquisition by Gilead Sciences for $115 per share in cash, plus a contingent value right of $5 per share, totaling around $7.8 billion [1][1][1] Company Overview - Arcellx's stock price increased from $64.11 to around $114 after the acquisition news, marking a significant rise and reaching new highs beyond late-2024 record levels [1][1][1] - The acquisition is expected to close in the second quarter, indicating a swift transition for Arcellx under Gilead's ownership [1][1][1] Industry Context - The merger and acquisition (M&A) activity in the biotech sector can expedite drug development timelines, providing quicker returns for investors compared to traditional pathways [1][1][1] - Gilead and Arcellx were already collaborating on the development of anito-cel, a treatment for multiple myeloma, which underscores the strategic rationale behind the acquisition [1][1][1] - Gilead's CEO expressed confidence in the potential of anito-cel, suggesting it could become a foundational treatment for multiple myeloma over time [1][1][1]

Summary of IDEAYA Biosciences Update - February 23, 2026 Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology - **Programs**: 9 clinical programs, with a focus on darovasertib in phase 3 studies for metastatic uveal melanoma [1][3] Key Points and Arguments Clinical Programs - **Darovasertib**: - Currently in two phase 3 randomized studies for first-line metastatic uveal melanoma and neoadjuvant indications [1] - Upcoming guidance on top-line results expected by the end of March 2026, focusing on median progression-free survival (PFS) as the primary endpoint [4][5] - Reported a solid 7-month PFS in previous presentations, with a follow-up of approximately 2 years [5][11] - **DLL3 Topo ADC (IDE-849)**: - Anticipated clinical data update by the end of 2026, with potential to be a best-in-class asset [2] - **MTAP Deletion Programs**: - Two clinical assets (PRMT5 and MAT2A) with opportunities for both monotherapy and combination therapy [2] - **KAT6/7 (IDE-574)**: - Entered phase 1, targeting a large patient population including breast and colorectal cancer [3] Trial Design and Expectations - **Trial Design**: - Simple randomized phase 3 comparison of darovasertib-crizotinib combination versus standard of care (checkpoint inhibitors) [15] - Control arm expected to show PFS of approximately 2-3 months based on meta-analyses [10][11] - **PFS and OS Analysis**: - The treatment arm is expected to outperform the control arm, with a significant buffer for achieving statistical significance [11][12] - Overall survival (OS) data shows a promising 21-month survival rate, with expectations for positive outcomes in the ongoing study [11][12][128] Patient Population and Disease Characteristics - **Uveal Melanoma**: - Majority of patients (over 90%) present with liver metastases, making liver-directed therapies critical [167][176] - Approximately one-third of patients have elevated LDH levels, indicating disease severity [180][181] Regulatory and Future Plans - **FDA Submission**: - Plans to file for approval based on PFS data, with OS data to be presented during the review process [136][186] - Anticipated timeline for filing and review is approximately 12 months, targeting first half of 2027 for potential approval [187] - **NCCN Guidelines**: - Plans to present data to the NCCN panel to support treatment inclusion for both HLA-A2 negative and positive patients [189] Neoadjuvant Study (OptimUM-09) - **OptimUM-09 Study**: - Focused on neoadjuvant treatment with promising results in tumor shrinkage and vision preservation [191] - Aims to change the treatment paradigm from surgical interventions to pharmacological management [195] Additional Important Information - **Safety Profile**: - Expected to be comparable to previous studies, with a focus on managing adverse events effectively [155] - Investigators are becoming more adept at handling treatment-related toxicities, which may lead to lower discontinuation rates [156] - **Data Review Process**: - The independent review of PFS is ongoing, with a target completion by the end of March 2026 [144] This summary encapsulates the key points from the IDEAYA Biosciences update, highlighting the company's focus on innovative oncology treatments, ongoing clinical trials, and strategic regulatory plans.

PresentationYigal NochomovitzCitigroup Inc., Research Division All right. Welcome, everyone, to the next session. This is day 2 of Citi's Virtual Oncology Summit. I'm Yigal Nochomovitz, biotech analyst here at Citi in New York. Remember, if you have questions for our speaker, who is Sean Boone, the CEO of Olema, and we'll start the conversation in a moment. If you have questions for him, just e-mail me, and I will relay them over. So Sean, thank you so much. Welcome. I appreciate the time. A lot going on i ...

For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...